{"id":107292,"date":"2021-02-17T13:44:19","date_gmt":"2021-02-17T13:44:19","guid":{"rendered":"https:\/\/fin2me.com\/?p=107292"},"modified":"2021-02-17T13:44:19","modified_gmt":"2021-02-17T13:44:19","slug":"gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases","status":"publish","type":"post","link":"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/","title":{"rendered":"GSK, Vir Biotech to expand COVID-19 research partnership for other diseases"},"content":{"rendered":"

(Reuters) – GlaxoSmithKline and Vir Biotechnology Inc will expand an existing partnership developing antibody therapies for COVID-19 to other diseases, the companies said on Wednesday.<\/p>

FILE PHOTO: Company logo of pharmaceutical company GlaxoSmithKline is seen at their Stevenage facility, Britain October 26, 2020. REUTERS\/Matthew Childs<\/figcaption>

As a part of the deal to research and develop monoclonal antibody treatments for influenza and other respiratory illnesses, GSK will make a further $120 million equity investment in Vir and an additional upfront payment of $225 million.<\/p>\n

Shares of San Francisco-based Vir, which is run by former Biogen Inc Chief Executive Officer George Scangos, rose 12.4% before the opening bell.<\/p>\n

The companies announced a partnership last year to research COVID-19 treatments. Unlike vaccines, antibody treatments are designed to be given to patients who have been diagnosed with the illness, with the aim of decreasing the severity of the disease.<\/p>\n

One of the companies\u2019 experimental therapies for COVID-19 is currently being studied in two global final-stage trials. Results from one of these studies are expected in the first quarter of 2021.<\/p>\n

The pandemic has spurred large pharma companies\u2019 interest in researching new ways to combat infectious pathogens, including influenza.<\/p>\n

The effectiveness of standard flu vaccines varies year to year based on how well researchers are able to predict that season\u2019s dominant strains months in advance.<\/p>\n

The effectiveness of the vaccine can also vary depending on the age of the recipient and other factors, according to the U.S. Centers for Disease Control and Prevention.<\/p>\n

The companies said they would work to further develop Vir\u2019s experimental treatment for influenza A, one of the viruses that causes flu.<\/p>\n

GSK and Vir said people 65 and older with underlying conditions have a higher risk of dying of the virus and historically, vaccines have had lower efficacy in this group.<\/p>\n

Source: Read Full Article<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

(Reuters) – GlaxoSmithKline and Vir Biotechnology Inc will expand an existing partnership developing antibody therapies for COVID-19 to other diseases, the companies said on Wednesday.FILE […]<\/p>\n","protected":false},"author":3,"featured_media":107291,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"yoast_head":"\nGSK, Vir Biotech to expand COVID-19 research partnership for other diseases - Fin2me<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GSK, Vir Biotech to expand COVID-19 research partnership for other diseases - Fin2me\" \/>\n<meta property=\"og:description\" content=\"(Reuters) – GlaxoSmithKline and Vir Biotechnology Inc will expand an existing partnership developing antibody therapies for COVID-19 to other diseases, the companies said on Wednesday.FILE [...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/\" \/>\n<meta property=\"og:site_name\" content=\"Fin2me\" \/>\n<meta property=\"article:published_time\" content=\"2021-02-17T13:44:19+00:00\" \/>\n<meta name=\"author\" content=\"Mark\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/02\/cnewsfotor14-3.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Mark\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/\",\"url\":\"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/\",\"name\":\"GSK, Vir Biotech to expand COVID-19 research partnership for other diseases - Fin2me\",\"isPartOf\":{\"@id\":\"https:\/\/fin2me.com\/#website\"},\"datePublished\":\"2021-02-17T13:44:19+00:00\",\"dateModified\":\"2021-02-17T13:44:19+00:00\",\"author\":{\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\"},\"breadcrumb\":{\"@id\":\"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/fin2me.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Markets\",\"item\":\"https:\/\/fin2me.com\/category\/markets\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"GSK, Vir Biotech to expand COVID-19 research partnership for other diseases\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fin2me.com\/#website\",\"url\":\"https:\/\/fin2me.com\/\",\"name\":\"Fin2me\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fin2me.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a\",\"name\":\"Mark\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fin2me.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g\",\"caption\":\"Mark\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GSK, Vir Biotech to expand COVID-19 research partnership for other diseases - Fin2me","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/","og_locale":"en_US","og_type":"article","og_title":"GSK, Vir Biotech to expand COVID-19 research partnership for other diseases - Fin2me","og_description":"(Reuters) – GlaxoSmithKline and Vir Biotechnology Inc will expand an existing partnership developing antibody therapies for COVID-19 to other diseases, the companies said on Wednesday.FILE [...]","og_url":"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/","og_site_name":"Fin2me","article_published_time":"2021-02-17T13:44:19+00:00","author":"Mark","twitter_card":"summary_large_image","twitter_image":"https:\/\/fin2me.com\/wp-content\/uploads\/2021\/02\/cnewsfotor14-3.jpg","twitter_misc":{"Written by":"Mark","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/","url":"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/","name":"GSK, Vir Biotech to expand COVID-19 research partnership for other diseases - Fin2me","isPartOf":{"@id":"https:\/\/fin2me.com\/#website"},"datePublished":"2021-02-17T13:44:19+00:00","dateModified":"2021-02-17T13:44:19+00:00","author":{"@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a"},"breadcrumb":{"@id":"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fin2me.com\/markets\/gsk-vir-biotech-to-expand-covid-19-research-partnership-for-other-diseases\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/fin2me.com\/"},{"@type":"ListItem","position":2,"name":"Markets","item":"https:\/\/fin2me.com\/category\/markets\/"},{"@type":"ListItem","position":3,"name":"GSK, Vir Biotech to expand COVID-19 research partnership for other diseases"}]},{"@type":"WebSite","@id":"https:\/\/fin2me.com\/#website","url":"https:\/\/fin2me.com\/","name":"Fin2me","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fin2me.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/fin2me.com\/#\/schema\/person\/ad0e9920e03d3b41c7ad02a18375d76a","name":"Mark","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fin2me.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/39b72719fb75a2d3c7d7695026648602?s=96&d=mm&r=g","caption":"Mark"}}]}},"_links":{"self":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/107292"}],"collection":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/comments?post=107292"}],"version-history":[{"count":0,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/posts\/107292\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media\/107291"}],"wp:attachment":[{"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/media?parent=107292"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/categories?post=107292"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/fin2me.com\/wp-json\/wp\/v2\/tags?post=107292"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}